Just a reminder that MSB has already looked at patients in the CHF phase 3 trial that were on Entresto and how Rexlemestrocel-L injection complimented these patients and showed great results ... check out from the 16:30 minute mark
"going to be very highly complimentary and in fact in the phase 3 trial we have looked at the data in that way and it is precisely what we have seen in that those patients who were on Entresto for example alone did better than any than those not on Entresto ...... but the combination of Entresto plus an injection of our cells appear to be highly synergistic"
.... makes sense now with the timing of the "extension' of the ARDS deal for 90 days and the release of the CHF results in December - synergy equals bigger partnership incorporating CHF with Novartis (IMO of course)
https://www.lsegissuerservices.com/spark/Mesoblast/events/7fec731a-4a40-4c41-af2d-23e1dd7fce2d
GLTAH
Cell Therapy News/Articles, page-8218
-
- There are more pages in this discussion • 10,211 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.495B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $1.819M | 1.396M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29972 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 2008 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |